Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.63
+1.4%		$1.02
$0.57
▼
$2.44
$25.50M0.062.06 million shs39,834 shs
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$4.02
-4.1%		$4.77
$3.18
▼
$71.50
$6.84M2.6130,539 shs15,384 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$3.29
+3.8%		$3.10
$2.72
▼
$12.15
$26.44M0.26579,589 shs61,376 shs
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
$1.77
-3.8%		$2.68
$1.11
▼
$4.70
$23.52M2.3143,973 shs180,721 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
+0.34%+2.92%-28.71%-62.41%-67.36%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-2.78%-3.68%-0.48%-33.91%-86.48%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
+1.60%+6.38%+3.59%-16.36%+7.46%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-3.41%-8.91%-35.66%-52.58%-54.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.63
+1.4%		$1.02
$0.57
▼
$2.44
$25.50M0.062.06 million shs39,834 shs
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$4.02
-4.1%		$4.77
$3.18
▼
$71.50
$6.84M2.6130,539 shs15,384 shs
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$3.29
+3.8%		$3.10
$2.72
▼
$12.15
$26.44M0.26579,589 shs61,376 shs
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
$1.77
-3.8%		$2.68
$1.11
▼
$4.70
$23.52M2.3143,973 shs180,721 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
+0.34%+2.92%-28.71%-62.41%-67.36%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-2.78%-3.68%-0.48%-33.91%-86.48%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
+1.60%+6.38%+3.59%-16.36%+7.46%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-3.41%-8.91%-35.66%-52.58%-54.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
1.00
SellN/AN/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
2.00
Hold$30.00646.27% Upside
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
2.67
Moderate Buy$11.00234.35% Upside
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ERNA, LTRN, EVAX, and BYSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/29/2026
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/14/2026
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/9/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/8/2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/29/2026
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/11/2026
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.75M14.77$0.12 per share5.46($0.59) per share-1.07
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$580K11.30N/AN/A$7.64 per share0.53
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
$7.53M3.64N/AN/A$2.04 per share1.61
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/A$0.58 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$1.01M-$0.12N/AN/AN/AN/AN/A-28.88%11/12/2026 (Estimated)
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$14.08M-$14.35N/AN/AN/AN/A-305.93%-169.86%11/6/2026 (Estimated)
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
-$7.71M-$1.21N/AN/AN/AN/A-61.43%-34.23%11/5/2026 (Estimated)
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$17.12M-$1.62N/AN/AN/AN/A-368.02%-148.62%11/11/2026 (Estimated)

Latest ERNA, LTRN, EVAX, and BYSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$0.54-$0.02+$0.52-$0.02$8.77 millionN/A
8/14/2026Q2 2026
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$0.38-$0.57-$0.19-$0.57N/AN/A
8/6/2026Q2 2026
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$3.30-$3.40-$0.10-$3.40N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/A
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
N/AN/AN/AN/AN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
0.70
0.70
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A
2.01
2.01
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
0.69
5.06
5.06
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/A
1.96
1.96

Institutional Ownership

CompanyInstitutional Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
70.55%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
11.04%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
28.62%

Insider Ownership

CompanyInsider Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.53%
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
41.64%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
8.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8041.12 million29.07 millionOptionable
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
101.63 million1.62 millionNo Data
Evaxion A/S - Sponsored ADR stock logo
EVAX
Evaxion A/S
608.34 million4.87 millionNo Data
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
2012.78 million11.70 millionOptionable

Recent News About These Companies

Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript
August 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lantern-pharma-ltrn-q2-2026-122823463.html
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260814100282/en/lantern-pharma-reports-second-quarter-2026-financial-results-and-provides-business-update/
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of ...
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/technology/ai/articles/lantern-pharma-nasdaq-ltrn-establishes-113000606.html
Lantern Pharma Spins Off Open-Medicine AI Platform
August 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lantern-pharma-spins-off-open-medicine-ai-platform?utm_source=marketbeat.com&utm_medium=referral
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
August 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260803318492/en/lantern-pharma-nasdaq-ltrn-establishes-open-medicine-ai-as-a-separate-company-to-commercialize-and-expand-its-multi-agent-ai-co-scientist-platform-for-the-transformation-of-medicine/
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
July 28, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260728012034/en/Lantern-Pharma-to-Advance-EMA-Cleared-Phase-1b2-Trial-of-LP-184-Zirdafulven-in-Biomarker-Selected-Advanced-Bladder-Cancer/
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
July 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260723600415/en/lantern-pharma-receives-uspto-notice-of-allowance-for-patent-covering-biomarker-guided-treatment-with-lp-184-zirdafulven-in-multiple-solid-tumor-cancers/
Why Lantern Pharma Inc.’s (LTRN) Stock Is Down 5.14%
July 8, 2026  |  aaii.comA
Lantern Pharma Launches ZetaOmics™ - an Autonomous, Intelligent "Computational Biologist" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
July 8, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/07/08/10411356.htm
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
July 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260708109056/en/Lantern-Pharma-Launches-ZetaOmics%E2%84%A2-%E2%80%94-an-Autonomous-Intelligent-%E2%80%9CComputational-Biologist%E2%80%9D-That-Brings-Expert-Grade-Bioinformatics-Biostatistics-Reasoning-to-Every-Cancer/
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
June 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260602549826/en/lantern-pharma-reports-harmonic%e2%84%a2-data-showing-lp-300-progression-free-survival-benefit-deepens-with-treatment-duration-in-egfr-exon-21-l858r-lung-cancer/
Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress
June 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lantern-pharma-highlights-harmonic-lp-300-phase-2-progress?utm_source=marketbeat.com&utm_medium=referral
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript
May 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/lantern-pharma-ltrn-q1-2025-143934474.html
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
May 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260519628990/en/lantern-pharma-announces-successful-outcome-of-fda-type-c-meeting-request-for-harmonic%e2%84%a2-phase-2-trial-of-lp-300-in-never-smokers-with-nsclc/
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
May 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260515994237/en/lantern-pharma-reports-first-quarter-2026-financial-results-and-provides-business-updates/
Insider Buying: Lantern Pharma (NASDAQ:LTRN) Director Acquires 48,544 Shares of Stock
May 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ltrn-insider-buying-and-selling-2026-05-15/
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
May 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/lantern-pharma-inc-announces-closing-200500626.html
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
May 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260513454439/en/lantern-pharma-inc.-announces-up-to-9.25-million-registered-direct-offering-with-existing-holders-and-a-single-institutional-investor/
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
May 11, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260511997550/en/Lantern-Pharma-to-Report-First-Quarter-2026-Operating-Financial-Results-on-May-15th-2026/
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript
April 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4897173-lantern-pharma-inc-ltrn-discusses-live-demonstration-of-withzeta-ai-ai-platform-for-rare

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Moderna logo displayed in a laboratory setting with a vaccine vial, petri dishes, and a microscope.
Moderna’s 177% Surge Has Investors Asking What Comes Next
By Sam Quirke | August 21, 2026
Illustration of a glass globe surrounded by gold coin stacks, symbolizing global financial markets and investment.
This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
By Jessica Mitacek | August 17, 2026
Illustration of a vial with an upward stock price chart and DNA double helix against a city skyline, symbolizing biotech growth.
2 Biotech Stocks Shaping Up for Major Breakouts
By Ryan Hasson | August 22, 2026
Conceptual illustration of a stock price chart rising sharply in green before turning red at the peak, set against storm clouds.
3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
By Dan Schmidt | August 22, 2026
Magnifying glass highlighting glowing candlestick chart bars against a dark background with an upward trending stock price line.
3 Overlooked Stocks Analysts Still Like as AI Trades Get Crowded
By Nathan Reiff | August 11, 2026
BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$0.63 +0.01 (+1.37%)
Closing price 03:53 PM Eastern
Extended Trading
$0.62 -0.01 (-1.86%)
As of 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Ernexa Therapeutics stock logo

Ernexa Therapeutics NASDAQ:ERNA

$4.02 -0.17 (-4.06%)
Closing price 04:00 PM Eastern
Extended Trading
$4.08 +0.07 (+1.62%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Evaxion A/S stock logo

Evaxion A/S NASDAQ:EVAX

$3.29 +0.12 (+3.79%)
Closing price 04:00 PM Eastern
Extended Trading
$3.29 0.00 (0.00%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Lantern Pharma stock logo

Lantern Pharma NASDAQ:LTRN

$1.77 -0.07 (-3.80%)
Closing price 04:00 PM Eastern
Extended Trading
$1.72 -0.04 (-2.54%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas